Nanoparticle-mediated targeted protein degradation (NanoTPD): Principles, rational design and mechanisms of degradation
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Protein Degradation and Inhibitors · Click Chemistry and Applications · Ubiquitin and proteasome pathways
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Kenten J.H., Roberts S.F., Controlling protein levels in eucaryotic organisms. US06306663(B1).
2. Protacs: chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation10.1073/pnas.141230798 ↗
3. Targeted protein degradation directly engaging lysosomes or proteasomes10.1039/D3CS00344B ↗
4. Redefining the scope of targeted protein degradation: translational opportunities in hijacking the autophagy–lysosome pathway10.1021/acs.biochem.1c00330 ↗
5. Recent advances in developing targeted protein degraders10.1016/j.ejmech.2024.117212 ↗
6. Targeted protein degradation: advances in drug discovery and clinical practice10.1038/s41392-024-02004-x ↗
7. Targeted protein degradation: from mechanisms to clinic10.1038/s41580-024-00729-9 ↗
8. E3 ubiquitin ligases: styles, structures and functions10.1186/s43556-021-00043-2 ↗
9. Strategy and design of in situ activated protein hydrolysis targeted chimeras10.1021/acsnano.4c11903 ↗
10. Advancements in delivery systems for proteolysis-targeting chimeras (PROTACs): overcoming challenges and expanding biomedical applications10.1016/j.jconrel.2025.113719 ↗
11. From conception to development: investigating PROTACs features for improved cell permeability and successful protein degradation10.3389/fchem.2021.672267 ↗
12. Targeted protein degradation for cancer therapy10.1038/s41568-025-00817-8 ↗
13. Chasing molecular glue degraders: screening approaches10.1039/D2CS00197G ↗
14. From PROTAC to TPD: advances and opportunities in targeted protein degradation10.3390/ph17010100 ↗
15. Recent advances of degradation technologies based on PROTAC mechanism10.3390/biom12091257 ↗
16. Targeted protein degradation: current molecular targets, localization, and strategies10.1016/j.drudis.2024.104178 ↗
17. AUTACs: cargo-specific degraders using selective autophagy10.1016/j.molcel.2019.09.009 ↗
18. The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system10.1038/s41467-022-28520-4 ↗
19. Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds10.1038/s41586-019-1722-1 ↗
20. Research advances in chaperone-mediated autophagy (CMA) and CMA-based protein degraders10.1021/acs.jmedchem.4c02681 ↗
21. Targeted degradation of membrane and extracellular proteins with LYTACs10.1038/s41401-024-01364-y ↗
22. Targeted degradation of extracellular secreted and membrane proteins10.1016/j.tips.2023.08.013 ↗
23. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins10.7150/thno.62686 ↗
24. New-generation advanced PRTACs as potential therapeutic agents in cancer therapy10.1186/s12943-024-02024-9 ↗
25. Nano-PROTACs: state of the art and perspectives10.1039/D3NR06059D ↗
26. Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques10.1016/j.ejmech.2023.115911 ↗
27. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine10.1016/j.addr.2019.04.008 ↗
28. Strategies for delivering nanoparticles across tumor blood vessels10.1002/adfm.202007363 ↗
29. PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application10.1080/10717544.2021.1938756 ↗
30. Multicompartment systems: a putative carrier for combined drug delivery and targeting10.1016/j.drudis.2021.12.007 ↗
31. Advancing proteolysis targeting chimera (PROTAC) nanotechnology in protein homeostasis reprograming for disease treatment10.1021/acsnano.4c09800 ↗
32. Nanotechnology-enabled targeted protein degradation for cancer therapeutics10.1002/wnan.2020 ↗
33. Targeted protein degradation technology and nanomedicine: powerful allies against cancer10.1002/smll.202207778 ↗
34. Nano-proteolysis targeting chimeras (nano-PROTACs) in cancer therapy10.2147/IJN.S448684 ↗
35. A PROTAC augmenter for photo-driven pyroptosis in breast cancer10.1002/adma.202313460 ↗
36. Enhanced protein degradation by intracellular delivery of pre-fused PROTACs using lipid-like nanoparticles10.1016/j.jconrel.2020.11.032 ↗
37. Chemotherapy-enabled colorectal cancer immunotherapy of self-delivery nano-PROTACs by inhibiting tumor glycolysis and avoiding adaptive immune resistance10.1002/advs.202309204 ↗
38. 2D-PROTACs with augmented protein degradation for super-resolution photothermal optical coherence tomography guided momentary multimodal therapy10.1016/j.cej.2022.137039 ↗
39. Glutathione-scavenging nanoparticle-mediated PROTACs delivery for targeted protein degradation and amplified antitumor effects10.1002/advs.202207439 ↗
40. Versatile nano-PROTAC-induced epigenetic reader degradation for efficient lung cancer therapy10.1002/advs.202202039 ↗
41. Self-assembled nano-PROTAC enables near-infrared photodynamic proteolysis for cancer therapy10.1021/jacs.3c04109 ↗
42. Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy10.1038/s41467-022-32050-4 ↗
43. A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity10.7150/thno.59020 ↗
44. A physiologically responsive nanocomposite hydrogel for treatment of head and neck squamous cell carcinoma via proteolysis-targeting chimeras enhanced immunotherapy10.1002/adma.202210787 ↗
45. Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy10.1038/s41392-024-01983-1 ↗
46. Tumor microenvironment responsive nano-PROTAC for BRD4 degradation enhanced cancer photo-immunotherapy10.1016/j.biomaterials.2025.123387 ↗
47. Checkpoint nano-PROTACs for activatable cancer photo-immunotherapy10.1002/adma.202208553 ↗
48. Smart nano-PROTACs reprogram tumor microenvironment for activatable photo-metabolic cancer immunotherapy10.1002/anie.202114957 ↗
49. Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy10.1038/s41467-021-23194-w ↗
50. Light-triggered PROTAC nanoassemblies for photodynamic IDO proteolysis in cancer immunotherapy10.1002/adma.202405475 ↗
51. In vivo self-assembly of PROTACs by bioorthogonal chemistry for precision cancer therapy10.1002/anie.202421713 ↗
52. A self-assembled nano-molecular glue (Nano-mGlu) enables GSH/H2O2-triggered targeted protein degradation in cancer therapy10.1021/jacs.4c11003 ↗
53. Biomarker-activated multifunctional lysosome-targeting chimeras mediated selective degradation of extracellular amyloid fibrils10.1016/j.chempr.2023.06.003 ↗
54. Targeted degradation of signal transduction and activator of transcription 3 by chaperone-mediated autophagy targeting chimeric nanoplatform10.1021/acsnano.3c09536 ↗
55. Supramolecular artificial nano-AUTACs enable tumor-specific metabolism protein degradation for synergistic immunotherapy10.1126/sciadv.adn8079 ↗
56. Nanoparticle-mediated targeted protein degradation: an emerging therapeutics technology10.1002/anie.202503958 ↗
57. Targeted biomolecule regulation platform: a split-and-mix PROTAC approach10.1021/jacs.2c12824 ↗
58. Persistent degradation of HER2 protein by hybrid nanoPROTAC for programmed cell death10.1021/acs.jmedchem.3c00013 ↗
59. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras10.1016/j.colsurfb.2020.110795 ↗
60. Targeted degradation of PD-L1 and activation of the STING pathway by carbon-dot-based PROTACs for cancer immunotherapy10.1002/anie.202218128 ↗
61. DNA framework-engineered chimeras platform enables selectively targeted protein degradation10.1038/s41467-023-40244-7 ↗
62. Unconventional PROTACs for targeted protein degradation in cancer therapy10.1002/anie.202507702 ↗
63. Nano proteolysis targeting chimeras (PROTACs) with anti-Hook effect for tumor therapy10.1002/anie.202308049 ↗
64. A co-assembly platform engaging macrophage scavenger receptor A for lysosome-targeting protein degradation10.1038/s41467-024-46130-0 ↗
65. Targeted degradation of ABCG2 for reversing multidrug resistance by hypervalent bispecific gold nanoparticle-anchored aptamer chimeras10.1039/D3CC00168G ↗
66. Nano-LYTACs for degradation of membrane proteins and inhibition of CD24/Siglec-10 signaling pathway10.1002/advs.202300288 ↗
67. Targeted protein degradation mediated by genetically engineered lysosome-targeting exosomes10.1021/acs.nanolett.3c03148 ↗
68. A bifunctional lysosome-targeting chimera nanoplatform for tumor-selective protein degradation and enhanced cancer immunotherapy10.1002/adma.202417942 ↗
69. Sonodynamic nano-LYTACs reverse tumor immunosuppressive microenvironment for cancer immunotherapy10.1021/jacs.4c13022 ↗
70. Logic gate activated lysosome targeting DNA nanodevice for controlled proteins degradation10.1002/adfm.202311722 ↗
71. Autophagy-activating nanoautophagosome-tethering compounds for targeted protein degradation specifically in tumor cells10.1021/acsmacrolett.4c00789 ↗
72. Nanoreceptors promote mutant p53 protein degradation by mimicking selective autophagy receptors10.1038/s41565-023-01562-5 ↗
73. A plug-and-play monofunctional platform for targeted degradation of extracellular proteins and vesicles10.1038/s41467-024-51720-z ↗
74. Lysosome-targeting protein degradation through endocytosis pathway triggered by polyvalent nano-chimera for AD therapy10.1002/adma.202411061 ↗
75. Multivalent RGD peptide-mediated nanochimera for lysosomal degradation of PDL1 protein10.1021/acs.nanolett.5c00341 ↗
76. Biomimetic nano-degrader based CD47-SIRPα immune checkpoint inhibition promotes macrophage efferocytosis for cardiac repair10.1002/advs.202306388 ↗
77. Targeted protein degradation via cellular trafficking of nanoparticles10.1038/s41565-024-01801-3 ↗
78. Prey for the proteasome: targeted protein degradation–a medicinal chemist's perspective10.1002/anie.202004310 ↗
79. Covalently engineered nanobody chimeras for targeted membrane protein degradation10.1021/jacs.1c08521 ↗
80. Proteasomal and autophagic degradation systems10.1146/annurev-biochem-061516-044908 ↗
81. Lysosome-targeting chimaeras for degradation of extracellular proteins10.1038/s41586-020-2545-9 ↗
82. An internalizing antibody specific for the human asialoglycoprotein receptor10.1089/hyb.2009.0019 ↗
83. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation10.1038/s41589-021-00770-1 ↗
84. Target reprogramming lysosomes of CD8+ T cells by a mineralized metal-organic framework for cancer immunotherapy10.1002/adma.202100616 ↗
85. Targeted protein degradation: mechanisms, strategies and application10.1038/s41392-022-00966-4 ↗
86. Intelligent modular DNA lysosome-targeting chimera nanodevice for precision tumor therapy10.1021/jacs.4c10010 ↗
87. Covalent LYTAC enabled by DNA aptamers for immune checkpoint degradation therapy
88. Structure and signalling in the IL-17 receptor family10.1038/nri2586 ↗
89. Tumor-associated macrophages: an accomplice in solid tumor progression10.1186/s12929-019-0568-z ↗
90. Peptide blocking of PD-1/PD-L1 interaction for cancer immunotherapy10.1158/2326-6066.CIR-17-0035 ↗
91. Asialoglycoprotein receptor mediated hepatocyte targeting – strategies and applications10.1016/j.jconrel.2015.02.022 ↗
92. Development of triantennary N-acetylgalactosamine conjugates as degraders for extracellular proteins10.1021/acscentsci.1c00146 ↗
93. Extracellular targeted protein degradation: an emerging modality for drug discovery10.1038/s41573-023-00833-z ↗
94. Protein labeling approach to improve lysosomal targeting and efficacy of antibody–drug conjugates10.1039/D0OB00265H ↗
95. Aptamer-based targeted protein degradation10.1021/acsnano.2c10379 ↗
96. Endocytosis and organelle targeting of nanomedicines in cancer therapy10.2147/IJN.S274289 ↗
97. Apoptotic extracellular vesicle formation via local phosphatidylserine exposure drives efficient cell extrusion10.1016/j.devcel.2023.05.008 ↗
98. Development of a nano-targeting chimera for the degradation of membrane and cytoplasmic proteins10.1016/j.actbio.2025.02.023 ↗
99. A self-destructive nanosweeper that captures and clears amyloid β-peptides10.1038/s41467-018-04255-z ↗
100. Emerging new concepts of degrader technologies10.1016/j.tips.2020.04.005 ↗